# Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

> **NCT05567406** · PHASE2 · WITHDRAWN · sponsor: **Kadmon, a Sanofi Company**

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** Belumosudil

## Key facts

- **NCT ID:** NCT05567406
- **Lead sponsor:** Kadmon, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06-16
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision.
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05567406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05567406, "Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05567406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*